Core Viewpoint - 博瑞医药 has abruptly withdrawn its plan for a private placement of A-shares for 2024, citing current market conditions and company circumstances as reasons for the decision [2] Group 1: Company Actions - The company initially planned to raise 500 million yuan through a private placement led by its actual controller, Yuan Jiandong, which was approved by the board and shareholders in May 2024 [2] - After a year of no progress on the private placement, the company revised its issuance plan multiple times before ultimately retracting the application [2][3] Group 2: Stock Price Fluctuations - 博瑞医药's stock price experienced significant volatility, rising from around 30 yuan to approximately 120 yuan within a month starting July 11, before plummeting back to 55.31 yuan [3] - The stock's dramatic rise and fall over three months has been likened to a "roller coaster" [3] Group 3: Financial Performance - The company's financial performance has deteriorated sharply, with net profit dropping by 84% to just over 17 million yuan in the first half of 2025 [4] - Revenue figures show a consistent decline, with total revenue for 2024 projected at 1.283 billion yuan, down from 1.180 billion yuan in 2023 [5] - The company reported a decline in net profit from 2022 onwards, with a significant drop in growth rates, indicating a troubling trend in profitability [5] Group 4: Company Background - 博瑞医药 is described as an innovative pharmaceutical company focused on research and development, aiming to establish a robust business model that integrates both generic and innovative drugs [5] - The company has undergone multiple rounds of financing since its IPO in 2019, including convertible bonds and a private placement, but faced regulatory scrutiny due to issues with fund management [6]

【 导读 】 博瑞医药定增筹划近一年半突然撤回，净利润暴跌八成，股价暴涨暴跌 记者注意到，近一年尤其是最近的三个月，博瑞医药股价出现了急剧变化。最初发行预案公布时，公司股价尚在30元附近，实控人独揽定 增无疑是合算的"买卖"，但随着"9·24"行情启动，加上今年以来创新药概念热炒，博瑞医药股价出现了大幅上涨的情况。 尤其是从7月11日开始之后的一个月，其股价更是快速上涨，短短一个月从55元最高涨到120元附近，8月中旬开始又持续暴跌，目前最新 股价跌到了55.31元。短短三个月，博瑞医药股价就坐了一轮大大的"过山车"。 除了股价，博瑞医药的业绩也出现了急剧变化，公司2019年在科创板上市，起初几年还能保持业绩正增长，但2022年开始出现小幅下滑， 2023年、2024年保持下滑趋势。到了2025年，公司业绩从小幅下滑转为断崖式下滑，今年上半年净利润仅有1700余万元，暴跌了 84%。 | 成长能力指标 | 24-12-31 | 23-12-31 | 22-12-31 | 21-12-31 | 20-12-31 | 19-12-31 | | --- | --- | --- | --- | --- | --- | ...